Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of vericiguat in adults with chronic HFrEF
CTR20220172Phase 3Active
- Sponsor
- Merck & Co.
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vericiguat in heart failure with reduced ejection fraction (HFrEF), sponsored by Merck & Co.. Started May 2022; status: active.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20220172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220172.